+

WO2002064167A3 - Biologically active agents - Google Patents

Biologically active agents Download PDF

Info

Publication number
WO2002064167A3
WO2002064167A3 PCT/GB2002/000575 GB0200575W WO02064167A3 WO 2002064167 A3 WO2002064167 A3 WO 2002064167A3 GB 0200575 W GB0200575 W GB 0200575W WO 02064167 A3 WO02064167 A3 WO 02064167A3
Authority
WO
WIPO (PCT)
Prior art keywords
prostaglandin
proteinaceous
agent
complex
biologically active
Prior art date
Application number
PCT/GB2002/000575
Other languages
French (fr)
Other versions
WO2002064167A2 (en
Inventor
Rodney William Kelly
Original Assignee
Medical Res Council
Rodney William Kelly
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Res Council, Rodney William Kelly filed Critical Medical Res Council
Publication of WO2002064167A2 publication Critical patent/WO2002064167A2/en
Publication of WO2002064167A3 publication Critical patent/WO2002064167A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A complex comprising a proteinaceous agent which is chemotactic for monocytes and/or neutrophils and a prostaglandin. A method of making a complex comprising a proteinaceous agent which is chemotactiv for monocytes and/or neutrophils and a prostaglandin, the method comprising the steps of admixing the proteinaceous cervical ripening agent and the prostaglandin under conditions in which they come into intimate contact. Preferably, the proteinaceous cervical ripening agent is MCP-1 or IL-8 or a derivative thereof. Preferably, the prostaglandin is PGE2. The complex or pharmaceutical compositions thereof are useful in ripening the cervix in a female in need thereof.
PCT/GB2002/000575 2001-02-10 2002-02-11 Biologically active agents WO2002064167A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0103354.7 2001-02-10
GBGB0103354.7A GB0103354D0 (en) 2001-02-10 2001-02-10 Biologically active agents

Publications (2)

Publication Number Publication Date
WO2002064167A2 WO2002064167A2 (en) 2002-08-22
WO2002064167A3 true WO2002064167A3 (en) 2003-04-17

Family

ID=9908517

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2002/000575 WO2002064167A2 (en) 2001-02-10 2002-02-11 Biologically active agents

Country Status (2)

Country Link
GB (1) GB0103354D0 (en)
WO (1) WO2002064167A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2682318C2 (en) * 2015-01-05 2019-03-19 Корнелл Юниверсити Compositions and methods for improving milk productivity and reproductive health of mammals based on use of il-8
US11464831B2 (en) 2015-01-05 2022-10-11 Cornell University Compositions and methods using IL-8 for improving health of mammals

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990008777A1 (en) * 1989-01-31 1990-08-09 The United States Of America, Represented By The Secretary, United States Department Of Commerce HUMAN DERIVED MONOCYTE ATTRACTING PURIFIED PROTEIN PRODUCT USEFUL IN A METHOD OF TREATING INFECTION AND NEOPLASM IN HUMAN BODY, AND THE CLONING OF FULL LENGTH cDNA THEREOF
US5624670A (en) * 1991-11-21 1997-04-29 Medical Research Council Use of interleukin-8 for inducing cervical ripening
US5908829A (en) * 1994-03-31 1999-06-01 Medical Research Council Use of MCP-1 for inducing ripening of the cervix

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990008777A1 (en) * 1989-01-31 1990-08-09 The United States Of America, Represented By The Secretary, United States Department Of Commerce HUMAN DERIVED MONOCYTE ATTRACTING PURIFIED PROTEIN PRODUCT USEFUL IN A METHOD OF TREATING INFECTION AND NEOPLASM IN HUMAN BODY, AND THE CLONING OF FULL LENGTH cDNA THEREOF
US5624670A (en) * 1991-11-21 1997-04-29 Medical Research Council Use of interleukin-8 for inducing cervical ripening
US5908829A (en) * 1994-03-31 1999-06-01 Medical Research Council Use of MCP-1 for inducing ripening of the cervix

Also Published As

Publication number Publication date
GB0103354D0 (en) 2001-03-28
WO2002064167A2 (en) 2002-08-22

Similar Documents

Publication Publication Date Title
EP2298812A3 (en) Remedies for juvenile chronic arthritis and related diseases
MY162623A (en) Immunoglobulin formulation and method of preparation thereof
WO2003044076A8 (en) Bioerodible poly(ortho esters) containing amine groups, and block copolymers containing them
HK1067544A1 (en) Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms
WO2002056900A3 (en) Use of slpi for treating chronic inflammatory intestinal diseases
ATE373464T1 (en) BIOADHESIVE SUSTAINED RELEASE THERAPEUTIC SYSTEMS
CA2396159A1 (en) Novel substituted benzimidazole dosage forms and method of using same
HK1066468A1 (en) Aqueous sustained-release formulations of proteins
WO2002055098A3 (en) Latency associated peptide for providing latency to pharmaceutically active proteins
AU2002335815A1 (en) High-concentration protein formulations and method of manufacture
MXPA03008420A (en) Solid orally-dispersible pharmaceutical formulation.
DE50105771D1 (en) IBUPROFEN-ACTIVE PREPARATION
ITRM20010476A0 (en) RECONSTRUCTED HUMAN CORNEAL EPITHELIUM SHEETS AND METHOD FOR THEIR OBTAINMENT.
AU2001267886A1 (en) Epoxycarboxylic acid amides, azides and amino alcohols and processes for preparation of alpha-keto amides by using them
WO2003020200A3 (en) A novel pharmaceutical compound and methods of making and using same
WO2002064167A3 (en) Biologically active agents
RS20050662A (en) Liquid formulations of tumor necrosis factor-binding proteins
MXPA03000471A (en) sHARMACEUTICALLY ACTIVE SULFONAMIDE DERIVATIVES BEARING BOTH LIPOPHILIC AND IONISABLE MOIETIES AS INHIBITORS OF PROTEIN JUNKINASES.
BRPI0413446A (en) hydroxyethylcellulose bioadhesive gel
AU2002341555A1 (en) Levothyroxine pharmaceutical compositions, methods of making and methods of administration
AU8799001A (en) Pharmaceutically active hydrophilic sulfonamide derivatives as inhibitors of protein junkinases
MY130445A (en) Novel formulations of alpha-2, 4-disulfophenyl-n-tert-butylnitrone
ITRM20010048A0 (en) METHOD FOR PREPARING PHYSIOLOGICALLY ACCEPTABLE AQUEOUS SOLUTIONS AND THE SOLUTIONS SO OBTAINED.
WO2003026621A3 (en) Method for making an oral pharmaceutical product with tell-tale agents, in particular of taste and resulting product
WO2004035023A8 (en) Use of molded bodies for external application

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载